PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Jul 18, 2019 → Mar 1, 2026
NCT ID
NCT04006457About PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
PF-06651600 + Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine + Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine is a phase 3 stage product being developed by Pfizer for Alopecia Areata. The current trial status is active. This product is registered under clinical trial identifier NCT04006457. Target conditions include Alopecia Areata.
What happened to similar drugs?
1 of 19 similar drugs in Alopecia Areata were approved
Approved (1) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006457 | Phase 3 | Active |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 40 |
| Deuruxolitinib + Placebo | Sun Pharmaceutical | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| minoxidil | Johnson & Johnson | Phase 3 | 40 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 40 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 47 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| Secukinumab + Placebo | Novartis | Phase 2 | 27 |
| Daxdilimab | Amgen | Phase 2 | 35 |
| Ritlecitinib | Pfizer | Pre-clinical | 30 |
| LITFULO | Pfizer | Pre-clinical | 30 |
| Ritlecitinib | Pfizer | Pre-clinical | 33 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 47 |